Patient 1 SIA stage | Creatinine, μmol/L | BNP, pmol/L | NT-proBNP, pmol/L | Prolactin, pmol/L |
---|---|---|---|---|
Blood samples (Status) | ||||
1 (Pre; +5 months) | 630 | N/A | N/A | 27,561 [13,438] |
2 (Pre; +5.5 months) | 600 | N/A | N/A | 41,682 [20,323] |
3 (Pre; +8.75 months) | 580 | 9410 [32,563; >400] | N/A | 37,398 [18,234] |
4 (Post; +8.75 months) | 330 | 5478 [18,958; >400] | N/A | 37,923 [18,490] |
5 (Pre; +10.75 months) | 600 | N/A | 25,060 [212,370; >1200] | 26,868 [13,100] |
6 (Post; +10.75 months) | 210 | N/A | 14,814 [125,540; >1200] | 18,254 [8,900] |
7 (Pre; +5 years)β | 518 | N/A | 16,846 [142,765; >1200] | 8087 [3,943] |
βBlood sample obtained during terminal Event Y. Anti-hypertension methyldopa was ceased for one year prior to this. | ||||
Patient 2 SIA stage | Creatinine, μmol/L | BNP, pmol/L | NT-proBNP, pmol/L | Prolactin, pmol/L |
Blood samples (Status) | ||||
1 (Inter; +1 day) | 763 | 79.2 [274; <225] | N/A | N/A |
Patient 2 Post-SIA stage | Creatinine, μmol/L | BNP, pmol/L | NT-proBNP, pmol/L | Prolactin, pmol/L |
Blood samples (Status) | ||||
1 (Post-Tx; +19 months) | 136 | 52 [180; <201] | 32.45 [275; <300] | 1103 [538] |
Patient 3 SIA stage | Creatinine, μmol/L | BNP, pmol/L | NT-proBNP, pmol/L | Prolactin, pmol/L |
Blood samples (Status) | ||||
1 (Inter; -7 days) | 588 | 14.8 [51.4; <225] | 118.47 [1004; <300] | 1389 [677] |